tiprankstipranks
Trending News
More News >
Avalo Therapeutics, Inc. (AVTX)
:AVTX
US Market

Avalo Therapeutics (AVTX) Income Statement

Compare
1,028 Followers

Avalo Therapeutics Income Statement

Last quarter (Q3 2025), Avalo Therapeutics's total revenue was $0.00, a decrease of -100.00% from the same quarter last year. In Q3, Avalo Therapeutics's net income was $-30.63M. See Avalo Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 441.00K$ 1.92M$ 18.05M$ 5.40M$ 6.70M
Gross Profit
$ 807.00K$ 640.00K$ 14.62M$ 3.91M$ 6.40M
Operating Expenses
$ 69.32M$ 27.99M$ 52.06M$ 86.04M$ 6.40M
Depreciation and Amortization
$ 169.00K$ 158.00K$ 166.00K$ 1.66M$ 1.84M
EBITDA
$ -68.34M$ -23.29M$ -37.27M$ -80.48M$ -45.45M
Operating Income
$ -68.51M$ -27.35M$ -37.44M$ -82.13M$ 0.00
Other Income/Expenses
$ 33.50M$ -4.18M$ -4.19M$ -2.41M$ -67.18M
Pretax Income
$ -35.02M$ -31.53M$ -41.63M$ -84.55M$ -67.18M
Net Income
$ -35.13M$ -31.54M$ -41.66M$ -84.38M$ -63.50M
Per Share Metrics
Basic EPS
$ -4.32$ -113.58$ -1.06K$ -2.33K$ -2.52K
Diluted EPS
$ -3.26$ -113.58$ -1.06K$ -2.33K$ -2.52K
Weighted Average Shares Outstanding
8.13M 277.73K 39.20K 36.19K 25.51K
Weighted Average Shares Outstanding (Diluted)
10.78M 277.73K 39.20K 36.19K 25.51K
Currency in USD

Avalo Therapeutics Earnings and Revenue History